Last mentioned: Mar 17, 2026
Clinical Evaluation
Anticipated delivery of therapeutic batches for Phase I/II clinical trials.
cGMP Manufacturing
Commencement of current Good Manufacturing Practice (cGMP) runs for clinical supply.
Process Development
Expected completion of initial process optimization and scale-up activities.
Program Initiation
BioCina officially starts the comprehensive manufacturing program for the Patry therapeutic.
BioCina has launched a comprehensive manufacturing program for the Patry proprietary injectable therapeutic, a novel treatment designed to alleviate delirium. This partnership marks a critical milestone in bringing a specialized solution to a high-need clinical area with limited current treatment options.
This page surfaces every story mentioning Patrys Limited across our healthcare coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running healthcare beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Patrys Limited was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |